NYSE : ADCT
ADC Therapeutics SA — Key statistics
Healthcare · Biotechnology · Switzerland
Last price 1.53 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 195.33M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 196.61M |
| Enterprise Value | 415.69M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 127.67M |
| Shares Outstanding | 127.67M |
| Shares Change (YoY) | +38.27% |
| Shares Change (QoQ) | +21.90% |
| Owned by Insiders (%) | 3.84% |
| Owned by Institutions (%) | 33.31% |
| Float | 81.56M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.53 |
| Forward PS | 2.39 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 5.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.03 |
| Quick Ratio | 2.86 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.80 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -19.57% |
| Return on Invested Capital (ROIC) | -25.47% |
| Return on Capital Employed (ROCE) | -48.72% |
| Weighted Average Cost of Capital (WACC) | 11.02% |
| Revenue Per Employee | $412,352 |
| Profits Per Employee | -$502,114 |
| Employee Count | 193 |
| Asset Turnover | 0.26 |
| Inventory Turnover | 7.83 |
Taxes
| Measure | Value |
|---|
| Income Tax | -404,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.86 |
| 52-Week Price Change | -65.47% |
| 50-Day Moving Average | 1.32 |
| 200-Day Moving Average | 2.47 |
| Relative Strength Index (RSI) | 54.30 |
| Average Volume (20 Days) | 1,566,083 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 6.34M |
| Short Previous Month | 5.39M |
| Short % of Shares Out | 4.97% |
| Short % of Float | 7.77% |
| Short Ratio (days to cover) | 3.44 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 79.58M |
| Gross Profit | -9.23M |
| Operating Income | -94.06M |
| Pretax Income | -97.31M |
| Net Income | -96.91M |
| EBITDA | -93.71M |
| EBIT | -94.06M |
| Loss Per Share | -$0.65 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 219.11M |
| Total Debt | 438.19M |
| Net Cash | -219.08M |
| Net Cash Per Share | -$1.72 |
| Equity (Book Value) | -228.21M |
| Book Value Per Share | -1.79 |
| Working Capital | 175.38M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -102.27M |
| Capital Expenditures | -32,000 |
| Depreciation & Amortization | 353,500 |
| Net Borrowing | n/a |
| Free Cash Flow | -102.30M |
| FCF Per Share | -$0.80 |
Margins
| Measure | Value |
|---|
| Gross Margin | -11.59% |
| Operating Margin | -118.19% |
| Pretax Margin | -122.28% |
| Profit Margin | -121.77% |
| EBITDA Margin | -117.75% |
| EBIT Margin | -118.19% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -38.27% |
| Shareholder Yield | -38.27% |
| Earnings Yield | -42.20% |
| FCF Yield | -50.72% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $3.33 |
| Price Target Difference | 116.43% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 29.97% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -8.02 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |